Gallop Oncology

📍 Boston, United States👥 2 employees
Biotechnology Research🌐 galloponcology.com
Website LinkedIn
Gallop Oncology is a clinical-stage biopharma company leading development of drugs targeting galectin-9, a pivotal oncogenic and immunosuppressive regulator of cancer processes We are focused on transforming treatment paradigms for both hematologic and solid tumor indications. Our lead asset, LYT-200, has received Fast Track and Orphan Drug Designations for the treatment of acute myeloid leukemia (AML) and head and neck squamous cell carcinoma (HNSCC). With its dual mechanism of action—direct tumor suppression and immune modulation—LYT-200 represents a novel, differentiated approach in oncology therapeutics.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
What industry is Gallop Oncology in?
Gallop Oncology operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Gallop Oncology based?
Gallop Oncology is headquartered in Boston, United States.